Quantcast

Latest Trubion Stories

2014-03-05 08:29:20

DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and) has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market" [http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Engineered antibodies are antibody based therapeutics, which are gaining increasing attention from...

2013-09-08 23:01:44

Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. Dallas, Texas (PRWEB) September 08, 2013 The global multiple sclerosis therapeutics market has the potential to grow to a value of $17.9 billion by 2019. The market is currently led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period...

2011-02-01 16:00:00

HAYWARD, Calif., Feb. 1, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, today announced that it has appointed Dr. Peter Thompson to its Board of Directors. Currently, Dr. Thompson is a venture partner with OrbiMed and is the founder and Managing Director of Strategicon Partners, an investment and management services company. In 2009, Dr....

2010-11-08 05:00:00

BOTHELL, WA, and VANCOUVER, Nov. 8 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the appointment of Michelle Burris to the position of executive vice president, operations and chief financial officer. Ms. Burris, a seasoned public company executive, brings over 20 years of financial and operations management experience to OncoGenex.  Ms. Burris, who will join the company in this capacity on January 3, 2011, is currently a member of the...

2010-10-26 15:30:00

ROCKVILLE, Md., Oct. 26 /PRNewswire/ -- MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART(TM)) products directed at two undisclosed cancer targets. MacroGenics' DART technology is a proprietary, bi-specific antibody platform in which a single recombinant molecule is able to...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.